CKD-MBD: impact on management of kidney disease.
Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.
Ogata
Hiroaki
H
Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan. ogatah@med.showa-u.ac.jp.
Koiwa
Fumihiko
F
Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Kinugasa
Eriko
E
Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan.
Akizawa
Tadao
T
Department of Nephrology, Showa University School of Medicine, Tokyo, Japan.
D000814:Aniline Compounds / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D002128:Calcium Metabolism Disorders / Q000188:drug therapy / Q000209:etiology; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use*; D000069449:Cinacalcet; D018450:Disease Progression; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000209:etiology; D054559:Hyperphosphatemia / Q000188:drug therapy / Q000209:etiology; D007811:Lanthanum / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use; D010627:Phenethylamines; D011073:Polyamines / Q000627:therapeutic use; D011437:Propylamines; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D000069603:Sevelamer; D014807:Vitamin D / Q000031:analogs & derivatives / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000188:drug therapy / Q000209:etiology; D014815:Vitamins / Q000627:therapeutic use*
D000814:Aniline Compounds; D002614:Chelating Agents; C107873:N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine; D009281:Naphthalenes; D010627:Phenethylamines; D011073:Polyamines; D011437:Propylamines; D014815:Vitamins; D014807:Vitamin D; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer; D000069449:Cinacalcet